Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

How AI Will Transform Biopharma: The Sequence of Change Matters

Ben Liu, CEO of Formation Bio, argues that AI will transform the pharmaceutical industry unevenly and sequentially. Some parts of drug disco

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

Should investors just buy anything with a hint of artificial intelligence, or try to find the parts of the AI supply chain where bottlenecks capture more of the value?

AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design

The article discusses recent advancements in AI-driven drug discovery, highlighting two key developments: 1) Analytica 2026, an event focuse

STAT+: Roche drug sets new standard for KRAS-driven lung cancer

India’s Generic Pharma Industry Is Sitting on a Formulation Data Time Bomb